Our Team

Stefanie Perna-Nacar is a seasoned executive with over 20 years of experience in marketing, communications, digital strategy, and public relations within the pharmaceutical industry. She excels at building brands, leading strategic communications, and driving business impact across global and U.S. markets.

Her expertise spans all phases of product development, from early pipeline to commercialization and lifecycle management. She has successfully launched and repositioned brands through innovative campaigns, omni-channel engagement, and high-impact PR initiatives. Having held leadership roles in both multinational corporations and biotech startups, she consistently delivers strategies that strengthen corporate reputation and stakeholder engagement.

As Head of U.S. Oncology Communications & Public Relations at GSK, Stefanie led all internal and external communications, developing award-winning PR and digital engagement campaigns that expanded brand adoption and set new corporate benchmarks. At TESARO Pharmaceuticals, she built and led the company’s marketing communications and digital strategy functions, spearheading multi-channel PR campaigns, including celebrity-driven initiatives.

Beyond communications, Stefanie has deep expertise in commercial strategy, serving as Vice President of Marketing at MorphoSys Pharmaceuticals and holding senior marketing and new product planning roles at Merck KGaA/EMD Serono, Infinity Pharmaceuticals, and Sanofi.

Her work has earned MM&M’s Marketer of the Year, PM360 Trailblazer Awards, and multiple DTC Ad Awards for excellence in brand strategy, public relations, and communications.

She holds a B.S. in Communications from Ohio University and is recognized for her strategic vision, innovative leadership, and ability to align marketing and communications to drive business success.

Robin Taylor, Ph.D. serves as the Chief Commercial Officer at Agenus, leading the commercial team and strategy, drawing on his extensive oncology global development and commercialization experience. His most recent leadership position was in the role of Chief Commercial Officer at Seagen, Inc. where he led the Commercial organization through a period of significant growth in preparation for the launches of PADCEV® (enfortumab vedotin), and TUKYSA® (tucatinib). Prior to this role Dr. Taylor was the Immuno-Oncology Franchise Head in the Oncology Business Unit at AstraZeneca, where he led the global medicine and product teams responsible for IMFINZI® (durvalumab), and IMJUDO® (tremelimumab). Robin spent the greatest part of his career in commercial roles of increasing responsibility at Genentech, a Member of the Roche Group, ultimately serving as the Lung and Cancer Immunotherapy Franchise Head, Global Product Strategy, responsible for the global development and commercialization of ALECENSA® (alectinib) and TECENTRIQ® (atezolizumab) across multiple indications.

Robin holds a Doctor of Philosophy in Molecular and Medical Genetics from University of Toronto, a Master of Business Administration from University of California Berkeley, and a Bachelor of Science from University of British Columbia.

Dr. Richard M. Goldberg serves as the Chief Development Officer at Agenus. An internationally recognized leader in gastrointestinal (GI) cancer treatment and research, Dr. Goldberg brings more than four decades of experience in academic oncology and cancer program leadership. Before joining Agenus, Dr. Goldberg served as Director of the West Virginia University Cancer Institute (WVUCI), overseeing its clinical, research, and educational missions. He was also a member of the leadership team for the WVU Health Sciences Center. Prior to WVU, he held senior leadership roles at top cancer centers, including Physician-in-Chief at both The Ohio State University’s James Cancer Hospital and the North Carolina Cancer Hospital at the University of North Carolina in Chapel Hill. He also served as Associate Director at the comprehensive cancer centers at both institutions and held division chief roles in hematology and oncology.

Throughout his career, Dr. Goldberg has been principal investigator, co-investigator, and mentor on numerous research and training grants funded by the National Cancer Institute. He has authored more than 320 peer-reviewed publications and is a frequent invited speaker at scientific conferences and academic institutions worldwide.

Dr. Goldberg earned his undergraduate degree cum laude in biology from Harvard University and received his medical degree from SUNY Upstate Medical University.

Zack is responsible for Investor Relations and Corporate Development activities at Agenus.  Previously, Zack was Director of Corporate Development at Valo Health, where he led several in-licensing and M&A efforts, including the company’s acquisition of Courier Therapeutics. Prior to Valo he spent several years at Flagship Pioneering where he helped found multiple new ventures created by the company, including Head of Corporate Development at CiBO Technologies. He earned his MBA at MIT Sloan, prior to which he was at Goldman Sachs & Co where he served as an analyst and associate on the business management team for the Private Banking unit. He holds a B.A. degree from Johns Hopkins University where he also played basketball on the Men’s Varsity team.